-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Analysts Set Morphic Holding, Inc. (NASDAQ:MORF) Price Target at $64.43
Analysts Set Morphic Holding, Inc. (NASDAQ:MORF) Price Target at $64.43
Morphic Holding, Inc. (NASDAQ:MORF – Get Rating) has earned an average recommendation of "Buy" from the eight ratings firms that are currently covering the company, Marketbeat.com reports. Eight equities research analysts have rated the stock with a buy recommendation. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $64.43.
MORF has been the topic of a number of research analyst reports. Wells Fargo & Company reduced their target price on Morphic from $79.00 to $77.00 and set an "overweight" rating on the stock in a research note on Thursday, August 4th. SVB Leerink began coverage on shares of Morphic in a research report on Wednesday, July 20th. They set an "outperform" rating and a $45.00 price target for the company. Royal Bank of Canada cut their price target on shares of Morphic from $76.00 to $70.00 and set an "outperform" rating for the company in a research report on Thursday, August 4th. BMO Capital Markets restated a "buy" rating and set a $83.00 price target on shares of Morphic in a research report on Friday, August 5th. Finally, Stifel Nicolaus assumed coverage on shares of Morphic in a research report on Tuesday, September 6th. They set a "buy" rating and a $44.00 price target for the company.
Get Morphic alerts:Morphic Stock Down 1.6 %
MORF opened at $29.56 on Thursday. The stock has a market cap of $1.14 billion, a PE ratio of -20.67 and a beta of 1.46. Morphic has a 52 week low of $19.23 and a 52 week high of $68.75. The business's fifty day simple moving average is $27.87 and its 200 day simple moving average is $30.24.
Institutional Trading of Morphic
Several institutional investors and hedge funds have recently bought and sold shares of the stock. Point72 Hong Kong Ltd increased its stake in shares of Morphic by 983.3% during the fourth quarter. Point72 Hong Kong Ltd now owns 715 shares of the company's stock valued at $34,000 after purchasing an additional 649 shares in the last quarter. Nisa Investment Advisors LLC bought a new stake in shares of Morphic during the second quarter valued at approximately $28,000. UBS Group AG bought a new stake in shares of Morphic during the first quarter valued at approximately $54,000. Group One Trading L.P. bought a new stake in shares of Morphic during the first quarter valued at approximately $56,000. Finally, Amalgamated Bank bought a new stake in shares of Morphic during the first quarter valued at approximately $138,000. 81.64% of the stock is currently owned by hedge funds and other institutional investors.Morphic Company Profile
(Get Rating)
Morphic Holding, Inc, a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; and preclinical trial to treat idiopathic pulmonary fibrosis and fibrosis diseases.
Featured Stories
- Get a free copy of the StockNews.com research report on Morphic (MORF)
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- The Auto Market Is Slowly Recovering, These Stocks May Outperform
- Is DocuSign On The Verge Of A Major Reversal?
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
Receive News & Ratings for Morphic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Morphic and related companies with MarketBeat.com's FREE daily email newsletter.
Morphic Holding, Inc. (NASDAQ:MORF – Get Rating) has earned an average recommendation of "Buy" from the eight ratings firms that are currently covering the company, Marketbeat.com reports. Eight equities research analysts have rated the stock with a buy recommendation. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $64.43.
据Marketbeat.com报道，Moric Holding，Inc.(纳斯达克代码：Morf-Get Rating)目前覆盖该公司的八家评级公司的平均推荐为买入。八位股票研究分析师已将该股评级为买入建议。在过去一年发布该股报告的分析师中，平均一年目标价为64.43美元。
MORF has been the topic of a number of research analyst reports. Wells Fargo & Company reduced their target price on Morphic from $79.00 to $77.00 and set an "overweight" rating on the stock in a research note on Thursday, August 4th. SVB Leerink began coverage on shares of Morphic in a research report on Wednesday, July 20th. They set an "outperform" rating and a $45.00 price target for the company. Royal Bank of Canada cut their price target on shares of Morphic from $76.00 to $70.00 and set an "outperform" rating for the company in a research report on Thursday, August 4th. BMO Capital Markets restated a "buy" rating and set a $83.00 price target on shares of Morphic in a research report on Friday, August 5th. Finally, Stifel Nicolaus assumed coverage on shares of Morphic in a research report on Tuesday, September 6th. They set a "buy" rating and a $44.00 price target for the company.
Morf已经成为许多研究分析师报告的主题。富国银行在8月4日(星期四)的一份研究报告中将Morphy的目标价从79.00美元下调至77.00美元，并对该股设定了“增持”评级。7月20日星期三，SVB Leerink在一份研究报告中开始对Morphi的股票进行报道。他们为该公司设定了“跑赢大盘”的评级和45.00美元的目标价。8月4日，加拿大皇家银行在一份研究报告中将Morphi的股票目标价从76.00美元下调至70.00美元，并为该公司设定了“跑赢大盘”的评级。蒙特利尔银行资本市场在8月5日(星期五)的一份研究报告中重申了“买入”评级，并为Morphi的股票设定了83.00美元的目标价。最后，Stifel Nicolaus在9月6日(星期二)的一份研究报告中对Morphi的股票进行了报道。他们为该公司设定了“买入”评级和44.00美元的目标价。
Morphic Stock Down 1.6 %
Moric股票下跌1.6%
MORF opened at $29.56 on Thursday. The stock has a market cap of $1.14 billion, a PE ratio of -20.67 and a beta of 1.46. Morphic has a 52 week low of $19.23 and a 52 week high of $68.75. The business's fifty day simple moving average is $27.87 and its 200 day simple moving average is $30.24.
Morf周四开盘报29.56美元。该股市值为11.4亿美元，市盈率为-20.67倍，贝塔系数为1.46。Moric的52周低点为19.23美元，52周高点为68.75美元。该业务的50日简单移动均线切入位为27.87美元，200日简单移动均线切入位为30.24美元。
Institutional Trading of Morphic
Morphi的机构交易
Morphic Company Profile
形态化的公司简介
(Get Rating)
(获取评级)
Morphic Holding, Inc, a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; and preclinical trial to treat idiopathic pulmonary fibrosis and fibrosis diseases.
生物制药公司Moric Holding，Inc.发现和开发用于治疗自身免疫、心血管、代谢性疾病以及纤维化和癌症的口服小分子整合素疗法。它的主要候选产品是Morf-057，这是一种A4？7特定的影响炎症的整合素抑制剂，目前处于治疗炎症性肠病的第一阶段临床试验；以及治疗特发性肺纤维化和纤维化疾病的临床前试验。
Featured Stories
专题报道
- Get a free copy of the StockNews.com research report on Morphic (MORF)
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- The Auto Market Is Slowly Recovering, These Stocks May Outperform
- Is DocuSign On The Verge Of A Major Reversal?
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
- 免费获取StockNews.com关于Morphy的研究报告(Morf)
- MarketBeat：回顾一周9/5-9/9
- 为网络安全股创纪录的季度做准备
- 汽车市场正在缓慢复苏，这些股票可能表现优异
- DocuSign是否即将发生重大逆转？
- 石油和天然气股票：投资可再生能源的安全途径
Receive News & Ratings for Morphic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Morphic and related companies with MarketBeat.com's FREE daily email newsletter.
接受Morphy Daily的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收最新新闻和分析师对Morphi及相关公司评级的每日简明摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧